Key Action Statement Profile: KAS 5B
| Aggregate evidence quality | Grade B |
| Benefits | Decreased frequency of AOM. Ability to treat AOM with topical antibiotic therapy. |
| Risks, harms, cost | Risks of anesthesia or surgery. Cost. Scarring of TM, chronic perforation, cholesteatoma. Otorrhea. |
| Benefits-harms assessment | Equilibrium of benefit and harm. |
| Value judgments | None. |
| Intentional vagueness | Option based on limited evidence. |
| Role of patient preferences | Joint decision of parent and clinician. |
| Exclusions | Any contraindication to anesthesia and surgery. |
| Strength | Option |
| Aggregate evidence quality | Grade B |
| Benefits | Decreased frequency of AOM. Ability to treat AOM with topical antibiotic therapy. |
| Risks, harms, cost | Risks of anesthesia or surgery. Cost. Scarring of TM, chronic perforation, cholesteatoma. Otorrhea. |
| Benefits-harms assessment | Equilibrium of benefit and harm. |
| Value judgments | None. |
| Intentional vagueness | Option based on limited evidence. |
| Role of patient preferences | Joint decision of parent and clinician. |
| Exclusions | Any contraindication to anesthesia and surgery. |
| Strength | Option |